Literature DB >> 21571368

Aberrant phosphorylation of STAT5 by granulocyte-macrophage colony-stimulating factor in infant cytomegalovirus infection mimicking juvenile myelomonocytic leukemia.

Nobuhiro Nishio1, Yoshiyuki Takahashi, Makito Tanaka, Yinyan Xu, Nao Yoshida, Hirotoshi Sakaguchi, Sayoko Doisaki, Asahito Hama, Hideki Muramatsu, Akira Shimada, Seiji Kojima.   

Abstract

Juvenile myelomonocytic leukemia (JMML) progenitor cells exhibit in vitro hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF). Phospho-specific flow cytometry using anti-phosphorylated STAT5 antibody is a new method recently reported to detect GM-CSF hypersensitivity of cells. However, colony assays using methylcellulose medium to measure GM-CSF-hypersensitivity remain as the current gold standard. Interestingly, cytomegalovirus (CMV) infection in infancy often presents with a variety of clinical symptoms that mimic JMML, with CMV giving a positive result by colony assay. We wanted to determine whether aberrant STAT5 activation occurs in CMV infection by using phospho-specific flow cytometry, and to ascertain whether this method is effective at discriminating CMV infection from JMML. Peripheral blood mononuclear cells from patients with JMML and CMV infection displayed an elevated proportion of p-STAT5 cells after low-dose GM-CSF stimulation when compared with cells from normal individuals. However, we found no significant differences in the percentage of p-STAT5 positive cells from patients with CMV infection and JMML at any doses of the GM-CSF doses used. We conclude that patients with CMV infection cannot be discriminated from patients with JMML by this new diagnostic method.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571368     DOI: 10.1016/j.leukres.2011.04.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.

Authors:  Shilpa Gandre-Babbe; Prasuna Paluru; Chiaka Aribeana; Stella T Chou; Silvia Bresolin; Lin Lu; Spencer K Sullivan; Sarah K Tasian; Julie Weng; Helene Favre; John K Choi; Deborah L French; Mignon L Loh; Mitchell J Weiss
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

2.  GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

Authors:  Eric Padron; Jeffrey S Painter; Sateesh Kunigal; Adam W Mailloux; Kathy McGraw; Jessica M McDaniel; Eunhee Kim; Christopher Bebbington; Mark Baer; Geoffrey Yarranton; Jeffrey Lancet; Rami S Komrokji; Omar Abdel-Wahab; Alan F List; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2013-04-30       Impact factor: 25.476

3.  Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia.

Authors:  D Hasegawa; C Bugarin; M Giordan; S Bresolin; D Longoni; C Micalizzi; U Ramenghi; A Bertaina; G Basso; F Locatelli; A Biondi; G Te Kronnie; G Gaipa
Journal:  Blood Cancer J       Date:  2013-11-15       Impact factor: 11.037

4.  Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment.

Authors:  Astrid Wintering; Christopher C Dvorak; Elliot Stieglitz; Mignon L Loh
Journal:  Blood Adv       Date:  2021-11-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.